Jeffrey Arcara
At a glance: Jeffrey Arcara is Chief Business Officer at Corvus Pharmaceuticals (CRVS). Their latest SEC Form 4, filed Nov 13, 2026, reported a purchase of $34K. On file: 4 purchase lines ($50K) and 0 sale lines ($0).
Disclosed holdings: about $48K of CRVS stock: 4,500 shares reported on their latest Form 4 (filed Nov 13, 2026), valued at the Nov 13, 2026 close of $10.64. This counts only CRVS shares reported to the SEC; it leaves out cash, other investments, options and unvested awards, so it is not total net worth.
Chief Business Officer at Corvus Pharmaceuticals, Inc. (CRVS)
Purchase track record
Not enough history. Based on 0 purchases with a full 90 days of price history.
Reported trades
| Filed | Stock | Type | Shares | Price | Value | Since |
|---|---|---|---|---|---|---|
| Nov 13 NewSEC | CRVSCorvus Pharmaceuticals, Inc.First buyNew position | Buy | 3,000new position | $11.46 | $34K | -7.2% |
| Nov 13 NewSEC | CRVSCorvus Pharmaceuticals, Inc.First buy | Buy | 4973,497 held (+17%) | $11.12 | $6K | -4.3% |
| Nov 13 NewSEC | CRVSCorvus Pharmaceuticals, Inc.First buy | Buy | 5034,000 held (+14%) | $10.37 | $5K | +2.6% |
| Nov 13 NewSEC | CRVSCorvus Pharmaceuticals, Inc.First buy | Buy | 5004,500 held (+12%) | $10.71 | $5K | -0.6% |
- Buy
Chief Business Officer Jeffrey Arcara bought $34K of CRVS at $11.46 — first open-market purchase in our records; opens a new position.
Follow Jeffrey Arcara
Get one email when Jeffrey Arcara files a new purchase or sale. Free.
At most one email a day about Jeffrey Arcara, plus the free Monday email. Already subscribed? Use the same email to add them. Unsubscribe anytime. Facts from public filings, not advice.